Samsung BioLogics took part in the "JP Morgan Healthcare Conference," the world’s largest global investment event held in San Francisco, the U.S. from Jan. 13.
Samsung BioLogics became the first Korean company to be assigned a main track in 2017 and the first Korean company to be assigned a "grand ballroom" since last year, drawing global investors’ attention.
The grand ballroom is a huge 800-seat presentation place that is reserved only for major global pharmaceutical companies such as Pfizer, Roche and Johnson & Johnson.
This year, Samsung BioLogics also made the announcement after being assigned the "grand ballroom" for the second straight year, earning its solid position in the global market and a high profile among major investors.
Samsung BioLogics presented its achievements, 2020 goals and mid- and long-term visions under the theme of "Innovation and Growth of Samsung in Biologics Industry" through the announcement on Jan. 15. The announcement was led by CEO Kim Tae-han and Vice President John Rim.
